Prakiraan wutah bathi kanggo taun ngarep Cingulate (CING)

Cingulate Inc. develops CNS drugs, demonstrating resilience to crises due to stable medical demand. Forward earnings per share dynamics help identify asset consolidation phases, while 17.50 captures the current state of the parameter. The company is implementing precision drug-release engineering systems for ADHD, although business success depends on clinical trial outcomes and strict liquidity management.

Cingulate Inc (CING): Prakiraan wutah bathi resik saben saham ing taun ngarep saka 04.07.2022 nganti 10.11.2026

CING (Cingulate): rincian analitis lan laporan miturut indikator

- rega saham lan konsensus proyeksi valuasi:

Rega saham Cingulate Inc|CING - Target konsensus

- rincian kapitalisasi pasar:

Kapitalisasi pasar Cingulate|CING - Nilai Dipunlarasaken Utang lan Kas

- indikator kapitalisasi buku:

Aset Bersih saben Siji Saham Cingulate|CING - Ekuitas Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku cingulate.com|CING - Gunggung Aset Perusahaan

- indikator total utang lan likuiditas perusahaan:

- data bathi resik lan rasio valuasi:

CING - Bathi resik perusahaan|Proyeksi bathi mangsa ngarep Cingulate Inc.|CING - Pangali P/E|Prakiraan rega marang bathi Cingulate Inc|CING - Rasio nilai perusahaan marang wutah bathi|Pangali EV/EBITDA Cingulate|CING - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Cingulate|CING - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan cingulate.com|CING - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Cingulate Inc.

Analisis umum perusahaan:Cingulate Inc., CING

This indicator measures expected earnings momentum for the coming year, aggregating analyst forecasts to determine the trajectory of fundamental value. For Cingulate (CING), which is developing extended-release delivery systems for ADHD medications, changes in the consensus net income growth estimate reflect market confidence in the commercial success of its new formulations. A positive trend in this metric confirms the high investment attractiveness and the resilience of the company's business model.

Pesaing Cingulate Inc. (CING)